Literature DB >> 16234479

Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.

C M G Cheung, P I Murray, C O S Savage.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16234479      PMCID： PMC1772907          DOI： 10.1136/bjo.2005.075689

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

Authors:  U Specks; F C Fervenza; T J McDonald; M C Hogan
Journal:  Arthritis Rheum       Date:  2001-12

2.  The unique antigen receptor signaling phenotype of B-1 cells is influenced by locale but induced by antigen.

Authors:  Michael J Chumley; Joseph M Dal Porto; John C Cambier
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

3.  Effective therapeutic use of rituximab in refractory Wegener's granulomatosis.

Authors:  Alistair J Ferraro; Clara J Day; Mark T Drayson; Caroline O Savage
Journal:  Nephrol Dial Transplant       Date:  2005-03       Impact factor: 5.992

4.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

5.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01
  5 in total
  22 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

Review 2.  New indications for biological therapies.

Authors:  Mariagrazia Catanoso; Nicolò Pipitone; Luca Magnani; Luigi Boiardi; Carlo Salvarani
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 3.  Biologic therapy for refractory scleritis: a new treatment perspective.

Authors:  Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani
Journal:  Int Ophthalmol       Date:  2015-08-29       Impact factor: 2.031

4.  Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.

Authors:  Julie Freidlin; Ira G Wong; Nisha Acharya
Journal:  Br J Ophthalmol       Date:  2007-10       Impact factor: 4.638

5.  Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.

Authors:  Achille Aouba; Christian Pagnoux; Boris Bienvenu; Alfred Mahr; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-12       Impact factor: 8.667

Review 6.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 7.  Biologic agents in the management of inflammatory eye diseases.

Authors:  Kira Michalova; Lyndell Lim
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

8.  Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Kohji Nishida
Journal:  Transl Vis Sci Technol       Date:  2012-10-22       Impact factor: 3.283

Review 9.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

Review 10.  Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.